Provider Learning Opportunities

COPD Begins in Childhood – Guidance for Health Care Providers

Signs and symptoms of COPD in the early stages can be easily overlooked, resulting in diagnostic delays and the worsening of the clinical condition.

This program has been approved for 1 contact hour Continuing Respiratory Care Education (CRCE) credit by the American Association for Respiratory Care. Course # 195395000.

This activity has been reviewed by the American Academy of Physician Associates Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid from 11/6/2025 to 11/5/2026. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-2014642.

Advancing COPD Care Through Precision Medicine and Patient Empowerment

This educational activity is intended for pulmonologists, pulmonology nurse practitioners, pulmonology physician assistants, and primary care physicians in the United States.

The goal of this activity is for learners to be better able to understand the importance of symptom recognition and the role of targeted treatments in individualizing COPD care and to better facilitate shared decision-making with patients to reduce the burden of disease.

Upon completion of this activity, participants will be able to:

• Identify challenges faced by patients with COPD in recognizing and managing symptoms
• Choose appropriate targeted treatment for patients with inadequately controlled COPD
• Apply evidence-based tools, such as COPD action plans and decision-support resources, to empower patients and optimize disease outcomes

Join leading COPD experts to explore the role of type 2 inflammation and eosinophils in COPD. Learn how to individualize treatment using guideline-based care and gain confidence in integrating new biologic therapies to improve outcomes for patients with eosinophilic COPD.

Learning Objectives:

• Summarize the new understanding of COPD disease onset, trajectory, and risk factors
• Explain the role of type 2 inflammation as a driver of the pathophysiology of COPD and lung remodeling for some people with difficult-to-control disease
• Describe the mechanism of action, efficacy, and safety of new biologic agents for COPD
• Discuss how to optimize the management of COPD by providing smoking-cessation counselling

New CME Education for Clinicians Treating Respiratory Disease

Patients with type 2 (T2) inflammatory conditions, including asthma, COPD with overlapping features, and other eosinophilic-driven diseases, often experience a high burden of illness.

Join a multidisciplinary panel of experts as they explore the connections between coexisting T2 conditions and the challenges they pose in clinical care.

Gain insights on the role of T2 inflammation in respiratory disease and the promise of emerging biologic therapies on Medlive.